AbelZeta’s C-CAR168 Receives FDA IND Clearance
San Diego, California, U.S., September 14, 2026 AbelZeta Therapeutics has announced that the U.S. Food and Drug Administration (FDA)...
CD20
Advertisement
Dr. Reddy’s Expands Access to Immunotherapy for Rare Head and Neck Cancer
JOHANNESBURG, South Africa / HYDERABAD, India, Aug. 3, 2026 Dr. Reddy’s Laboratories South Africa announced the registration of an...
Dr. Reddy’s Laboratories Secures U.S. FDA Approval for Rituximab Biosimilar
HYDERABAD, India, Aug. 1, 2026 Dr. Reddy’s Laboratories Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Genmab and AbbVie Clarify EPCORE DLBCL-1 Phase 3 Results
COPENHAGEN, Denmark and NORTH CHICAGO, Ill., July 23, 2026 Genmab and AbbVie have issued a clarification regarding the Phase...
Montefiore Einstein Expands CGM Use to Improve Diabetes Care
BRONX, New York, July 6, 2026 Montefiore Einstein investigators have published new research demonstrating that expanding the use of...
Advertisements
AMO Pharma Aligns Global Trial Plan for AMO-02 in cDM1
LONDON, United Kingdom, July 6, 2026 AMO Pharma Limited has announced a significant regulatory milestone for its investigational therapy...
AbbVie Wins EU Approval for TEPKINLY in Follicular Lymphoma
NORTH CHICAGO, Illinois, July 6, 2026 AbbVie has announced that the European Commission (EC) has granted marketing authorization for...
TG Therapeutics Launches Phase 2 BRIUMVI Trial
NEW YORK, July 6, 2026 TG Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI®...
Roche’s Gazyva Moves Closer to Public Access in Canada for Lupus Nephritis
MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...
Advertisement
